Tern Plc – Device Authority new contract win valued at over US$1.2 million

TERN

Tern Plc (LON:TERN), the company focused on value creation from Internet of Things technology businesses, has noted that Device Authority Limited has expanded its business and technology relationship with an existing tier one automotive supply chain customer via a new contract win valued at over US$1.2 million over five years, for expanded deployment of Device Authority’s KeyScaler® technology. Tern holds 53.8% of Device Authority’s equity.

This broader adoption of Device Authority’s KeyScaler® platform will enable this automotive supply chain customer to transform their long-term usage of the platform to develop a ‘secure identities’ manufacturing model for use across its global factories, positioning Device Authority as a key strategic partner for the customer, working collaboratively over the longer term.

Device Authority’s agreement with the global automotive supplier follows a contract secured by Device Authority in November 2022, in partnership with key strategic channel partners, with one of Europe’s main energy providers. This agreement will see Device Authority’s KeyScaler® platform integrated with existing and new services, providing identity management services for existing and next generation connected infrastructure. The contract has a projected value for Device Authority of approximately US$500,000 over the next three years, with the objective of protecting the energy company’s customers from cyber and ransomware attacks by providing trust for their IoT devices.

Commenting Al Sisto, CEO of Tern, said:

“We are delighted with the rapid progress that Device Authority is making in growing its revenue base, particularly via long term contracts with industry leaders.  The previous hard-fought wins with these leading companies are now being transformed into multi-year agreements.  Device Authority is validating the industry recognition it has already received from groups such as ABI Research* with these significant new contract wins, which will help them remain an industry leader in IoT device identity lifecycle management.

“2022 is proving to be a pivotal year for Device Authority following the strategic investment from Venafi in December 2021.  Tern and its co-investors are very pleased to see Device Authority enter into expanded multi-year agreements with some of the world’s leading IoT technology companies who are taking advantage of the features in Device Authority’s KeyScaler® platform to help provide significant long-term benefits to their customers.”

Note:

*https://www.abiresearch.com/market-research/product/7779608-iot-device-identity-lifecycle-management/

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Device Authority targets cyber resilience opportunity at TechWorks Summit 2026

Device Authority will focus on continuous IoT and OT compliance, AI and quantum risk at TechWorks Summit 2026 as it strengthens its position in connected-device security.

Talking Medicines builds a more defensible AI model for life sciences

Talking Medicines is combining proprietary healthcare intelligence, AI agents and orchestration to build a more specialised AI platform for life sciences.

Fundamental XR builds case for wider surgical simulation adoption

Fundamental XR is expanding the role of virtual simulation in surgical training as hospitals integrate the technology into structured education programmes.

Device Authority strengthens position in machine identity and Zero Trust Security

Device Authority’s inclusion in two 2026 Gartner Hype Cycle reports reinforces its positioning in machine identity, IoT authentication and Zero Trust security.

Talking Medicines highlights strategic value of patient journey intelligence

Patient journey intelligence can help healthcare organisations identify care barriers and design more responsive pathways around real patient experiences.

Evidence-based care pathways support more consistent healthcare delivery

Evidence-based care pathways can improve diagnosis, treatment consistency and the integration of new therapies into routine care.

Search